Recovery of Bi-213 from an Ac-225 Cow: Application to the Radiolabeling of Antibodies with Bi-213
Alpha particle-emitting radionuclides are among the most promising nuclides for the treatment of metastatic cancers.1 Because of their short range (60 to 100 μm) and high Linear Energy Transfer (LET) values, alpha-emitters can deliver a very large radiation dose over the distance of a few cell diameters. When alpha-emitters are linked to tumor seeking monoclonal antibodies (mAbs), the resulting product is a potentially powerful cancer therapeutic. Efforts are underway in many laboratories, including ours, to develop alpha-emitting mAb systems.
KeywordsLinear Energy Transfer Chelate Agent Transuranium Element High Linear Energy Transfer Bifunctional Chelate Agent
Unable to display preview. Download preview PDF.
- 2.D.S. Wilber, Potenial Use of Alpha Emitting Radionuclides in the Treatment of Cancer, Antibody, Immunoconjugates and Radiopharmaceuticals. 4:85–97.Google Scholar
- 3.M.W. Brechbiel, C.G. Pippin, T.J. McMurry, D. Milenic, M. Roselli, D. Colcher, and O.A. Gansow, An Effective Chelating Agent for Labelling of Monoclonal Antibody with Bi-212 for α-Particle Mediated Radioimmunotherapy. J. Chem. Soc. Chem. Commun., 1169–1170 (1991).Google Scholar
- 5.M.W. Geerlings, Radionuclides for Radioimmunotherapy: Criteria for Selection. Int. Journ. Biol. Markers, in press.Google Scholar
- 6.M.W. Geerlings, F.M. Kaspersen, C. Apostolidis, and R. Van Der Hout, The Feasibility of Ac-225 as a Source of α-particles in Radioimmunotherapy, Nucl. Med. Commun. 14:121–125 (1993).Google Scholar
- 7.M.W. Geerlings, Radioimmunotherapy Using α-Particles Emission. Int. Patent WO 90/15625 (1990).Google Scholar